Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection
Authors:
- Calvin CohenCCCalvin Cohen
- Joseph GatheJGJoseph Gathe
- Peter ShalitPSPeter Shalit
- Trevor HawkinsTHTrevor Hawkins
- Hui C. LiuHLHui C. Liu
- Anita A. MathiasAMAnita A. Mathias
- Steven L. ChuckSCSteven L. Chuck
- Brian P. KearneyBKBrian P. Kearney
- David R. WarrenDWDavid R. Warren
- 24 September 2011
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 25 (15) , 1881-1886
Abstract
To assess efficacy and safety of cobicistat versus ritonavir as pharmacoenhancers for atazanavir when administered with emtricitabine/tenofovir df as initial treatment for HIV-1 infection. Randomized, partially placebo-controlled, double-blind, multicenter study. Antiretroviral treatment-naive adults, screening HIV-1 RNA of at least 5000 copies/ml and CD4 cell count more than 50 cells/μl. Randomized 2 : 1 (stratified by HIV RNA ≤ or >100 000 copies/ml) to receive placebo-blinded once-daily cobicistat 150 mg or ritonavir 100 mg with open-label atazanavir and fixed-dose emtricitabine/tenofovir df. Efficacy and safety at weeks 24 and 48. Eighty-four percent of ATV/co participants and 86% of ATV/r participants suppressed HIV-1 RNA (<50 copies/ ml) at week 24, and 82 and 86% at week 48, respectively, and mean CD4 cell count increased 203 and 199 cells/μl at week 24 and 208 and 177 cells/μl at week 48, respectively. Study treatment discontinuation due to adverse events occurred in 4% ATV/co and in 3% ATV/r participants through 48 weeks. Treatment-related adverse events occurred in 36% ATV/co and 48% ATV/r participants; hyperbilirubinemia occurred in 96 and 100%, and ocular icterus or jaundice occurred in 14 and 17%, respectively. Mean estimated glomerular filtration rate (Cockcroft–Gault, ml/min) decrease occurred in both treatment groups and was evident at week 2 (ATV/co −9, ATV/r −4), reached a nadir by week 24 (−15, −14, respectively), and did not progress further through week 48 (−13, −14). Using cobicistat and ritonavir as pharmacoenhancers for atazanavir and administered with emtricitabine/tenofovir df achieved comparable rates of virologic suppression and CD4 cell count increase with satisfactory safety profiles.Keywords
This publication has 9 references indexed in Scilit:
- Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel PharmacoenhancerACS Medicinal Chemistry Letters, 2010
- Biological Profiling of GS-9350, a Novel Pharmacoenhancer that Lacks Anti-HIV Activity and Exhibits Low Potential for Metabolic Adverse Effects In VitroAntiviral Research, 2010
- Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV ActivityClinical Pharmacology & Therapeutics, 2009
- Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERTAIDS Research and Therapy, 2008
- Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C->T Polymorphism at the Multidrug Resistance Gene 1Clinical Infectious Diseases, 2006
- The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individualsAIDS, 1999
- RitonavirClinical Pharmacokinetics, 1998
- Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patientsAIDS, 1997
- Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavirAntimicrobial Agents and Chemotherapy, 1997